3 documents found, page 1 of 1
Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocyto...
Krzywicka, Katarzyna; van de Munckhof, Anita; Zimmermann, Julian; Bode, Felix J.; Frisullo, Giovanni; Karapanayiotides, Theodoros; Pötzsch, BerndCerebral venous thrombosis (CVT) is the most common and severe manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT), which is a rare side effect of the SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca/Oxford). The absolute risk of VITT and VITT-related CVT is estimated at 20 and 8 per million first doses of ChAdOx1 nCoV-19, respectively. So far, no definite VITT cases occurring a...
Outcomes of cerebral venous thrombosis due to vaccine-induced immune thrombotic...
van de Munckhof, Anita; Lindgren, Erik; Kleinig, Timothy J.; Field, Thalia S.; Cordonnier, Charlotte; Krzywicka, Katarzyna; Poli, SvenBackground: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. Methods: We used data from an international registry of patients ...
Acute symptomatic seizures in cerebral venous thrombosis
Lindgren, Erik; Silvis, Suzanne M.; Hiltunen, Sini; Heldner, Mirjam R.; Serrano, Fabiola; de Scisco, Michele; Zelano, Johan; Zuurbier, Susanna M.Objective: To identify characteristics, predictors, and outcomes of acute symptomatic seizures (ASS) in cerebral venous thrombosis (CVT), we investigated 1,281 consecutive adult patients with CVT included from 12 hospitals within the International CVT Consortium. Methods: We defined ASS as any seizure between symptom onset and 7 days after diagnosis of CVT. We stratified ASS into prediagnosis and solely postdia...